As of June 7, 2025, CRISPR Therapeutics AG (CRSP) reports a ROE (Return on Equity) of -18.96%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of CRISPR Therapeutics AG's ROE (Return on Equity)
Over recent years, CRISPR Therapeutics AG's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | -18.96% |
| 2023-12-31 | -8.16% |
| 2022-12-31 | -34.67% |
| 2021-12-31 | 15.74% |
| 2020-12-31 | -20.97% |
This slight downward trend highlights how CRISPR Therapeutics AG manages its efficiency in generating profits from shareholders' equity over time.
Comparing CRISPR Therapeutics AG's ROE (Return on Equity) to Peers
To better understand CRISPR Therapeutics AG's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| CRISPR Therapeutics AG (CRSP) | -18.96% |
| Ascendis Pharma A/S (ASND) | 357.68% |
| Halozyme Therapeutics Inc (HALO) | 122.06% |
| Basilea Pharmaceutica AG Allschwil (BSLN.SW) | 95.80% |
| ADC Therapeutics SA (ADCT) | 77.89% |
| Arena Pharmaceuticals Inc (ARNA) | 37.11% |
Compared to its competitors, CRISPR Therapeutics AG's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.